XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1

CONCENTRATIONS	3 Months Ended
	Mar. 31, 2022
CONCENTRATIONS
CONCENTRATIONS	(12)   CONCENTRATIONS For the three months ended March 31, 2022, the Company sourced approximately 30% of the components for its electrotherapy products from two significant vendors. For the three months ended March 31, 2021 the Company sourced approximately 32% of components from two significant vendors. Management believes that its relationships with suppliers are good; however, if the relationships were to be replaced, there may be a short-term disruption to operations, a period of time in which products may not be available and additional expenses may be incurred. At March 31, 2022, the Company had receivables from one third-party payers that made up approximately 19% of the net accounts receivable balance. At December 31, 2021, the Company had receivables from one third-party payer which made up approximately 22% of the net accounts receivable balance.

X

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479

+ Details

Name:	us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration